Today: 18 November 2025
Subscribe
Browse Category

Medical Research News 11 August 2025 - 12 November 2025

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) extended this week’s rally on Wednesday as investors digested fresh late‑stage results for its investigational oral PCSK9 inhibitor and an FDA clearance that supports broader precision use of Keytruda-based therapy. Below is what changed today and how it fits into Merck’s 2025 storyline. Today’s highlights at a glance Market move: why MRK is in focus today Merck shares traded higher on Wednesday after back‑to‑back catalysts in cardiometabolic and oncology. The stock’s strength follows AHA 2025 presentations showing that enlicitide—a once‑daily oral PCSK9 inhibitor—cut LDL‑C by 55.8% at 24 weeks vs. placebo in broad hypercholesterolemia
12 November 2025
 ·  ·  ·  ·  · 
Nobel Prize 2025: How Immune “Security Guards” Stop Autoimmune Disease

Nobel Prize 2025: How Immune “Security Guards” Stop Autoimmune Disease

A Breakthrough in Immune Self-Control In a landmark recognition for immunology, the 2025 Nobel Prize in Physiology or Medicine has been awarded to three scientists who unlocked how the immune system keeps itself from going rogue. Mary E. Brunkow (Institute for Systems Biology, Seattle), Fred Ramsdell (Sonoma Biotherapeutics, San Francisco), and Shimon Sakaguchi (Osaka University, Japan) earned the prize “for their discoveries concerning peripheral immune tolerance that prevents the immune system from harming the body” nobelprize.org. In essence, they found the body’s own “off-switch”: a mechanism that stops immune cells from attacking healthy tissues. Their work solved a medical mystery
6 October 2025
 ·  ·  ·  · 
Weekend Science Bonanza: Breakthroughs From Space to Superbugs

Weekend Science Bonanza: Breakthroughs From Space to Superbugs

Space & Astronomy Humanity’s search for cosmic neighbors hit a celebratory peak. NASA announced it has confirmed over 6,000 exoplanets – planets orbiting other stars – just three decades after finding the very first such world entechonline.com. This tally reflects an explosion of discoveries by telescopes like Kepler and TESS. “Each of the different types of planets we discover gives us information about… how common planets like Earth might be,” explained Dr. Dawn Gelino, who leads NASA’s exoplanet program, noting that every discovery helps us inch closer to answering the ultimate question of whether we’re alone sciencealert.com. The 6,000-planet milestone
21 September 2025
 ·  ·  ·  ·  ·  · 
CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

Breaking the Genetic “Spell” of a Liver Disease Phenylketonuria (PKU) is a hereditary metabolic liver disorder where a single DNA typo disrupts the PAH enzyme that breaks down phenylalanine, an amino acid nature.com fiercebiotech.com. Without a working PAH enzyme, phenylalanine builds up to toxic levels, causing brain damage, intellectual disability, and seizures if untreated. Newborn screening identifies PKU early, and patients are put on a strict lifetime diet limiting protein (to keep blood Phe 120–360 µM) pennmedicine.org fiercebiotech.com. Even with dietary control and medications, many patients struggle – foods high in protein are largely off-limits, and even newer drugs like
15 September 2025
 ·  ·  ·  · 
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Regulatory Approvals & Clinical Milestones Pharma & Biotech Industry Moves Startups & Innovation Highlights Medical Research & Innovation Public Health & Policy Developments Sources: Ionis HAE drug approval pharmexec.com biopharmadive.com; BioPharmaDive on Dawnzera pricing and positioning biopharmadive.com biopharmadive.com; AbbVie Rinvoq AA trial via FiercePharma fiercepharma.com; Lancet Neurology SAPPHIRE trial results neurologylive.com neurologylive.com; Reuters – Kite/Gilead’s Interius acquisition reuters.com and Interius press release interiusbio.com; PharmExec on XOMA-Mural deal ts2.tech; Reuters – J&J $2B NC facility and quote ts2.tech ts2.tech; Reuters – Apollo Hospitals stake sale ts2.tech; BiopharmaTrend on Kyorin adopting Elix AI platform biopharmatrend.com biopharmatrend.com; Laotian Times – Amgen Golden Ticket
23 August 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Major Corporate & Industry Announcements Clinical Trials & Drug Regulatory Updates Scientific & Medical Research Breakthroughs (Note: The above research highlights were reported in peer-reviewed journals and scientific news outlets around this time, underlining the broader scientific context during the news cycle.) Public Health & Policy Highlights Sources: Key information in this report is drawn from reputable industry and news outlets including Reuters reuters.com reuters.com, Fierce Biotech/Pharma fiercebiotech.com fiercebiotech.com, Endpoints News, STAT, and official statements from organizations like the FDA, EMA, WHO, and leading medical journals. For full details and additional context, please refer to the cited sources inline.
20 August 2025
 ·  ·  ·  ·  · 
Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

IO Biotech’s Phase 3 melanoma vaccine Cylembia added to Merck’s Keytruda narrowly missed statistical significance, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. Fosun Pharma’s deal with Expedition Therapeutics grants rights outside Greater China to XH-S004, a first-in-class oral DPP-1 inhibitor for chronic respiratory diseases, in a pact potentially worth up to $645 million including $120 million upfront and up to $525 million in milestones. NextRNA Therapeutics announced on August 11 it is winding down operations after cash constraints, leaving about 27 employees. FDA approved ketamine (brand name KETARx) from PharmaTher Holdings for surgical anesthesia
12 August 2025
 ·  ·  ·  · 
Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Novartis announced that two Phase III trials, NEPTUNUS-1 and NEPTUNUS-2, met their primary endpoints in Sjögren’s disease, marking the first global Phase III evidence of significant disease activity reduction with ianalumab and its dual B-cell depletion and BAFF signaling blockade. IO Biotech will disclose topline results from its Phase III melanoma trial of Cylembio (IO102-IO103) in combination with Merck’s Keytruda (pembrolizumab) as a first-line therapy, with an August 11 webcast planned and the therapy having earned Breakthrough Therapy designation. GSK’s gepotidacin received Priority Review from the U.S. FDA for uncomplicated gonorrhea, with a decision expected by December and the potential
11 August 2025
 ·  ·  ·  · 
Go toTop